<div id="readability-page-1"><p>Sheets Smith Investment Management acquired a new position in shares of  Journey Medical Corporation (NASDAQ:DERM - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 132,904 shares of the company's stock, valued at approximately $946,000. Sheets Smith Investment Management owned approximately 0.51% of Journey Medical at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Journey Medical</strong> alerts:</span></p></div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the company. Titleist Asset Management LLC lifted its holdings in  Journey Medical by 18.3% in the first quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock valued at $76,000 after acquiring an additional 2,000 shares during the period.  Police &amp; Firemen s Retirement System of New Jersey purchased a new position in shares of  Journey Medical during the 2nd quarter worth about $29,000.  Bank of America Corp DE raised its holdings in shares of  Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock worth $30,000 after buying an additional 4,048 shares during the period.  Raymond James Financial Inc. bought a new stake in shares of  Journey Medical during the second quarter worth $36,000.  Finally, Pale Fire Capital SE boosted its position in  Journey Medical by 19.0% in the 2nd quarter. Pale Fire Capital SE now owns 32,458 shares of the company's stock valued at $233,000 after buying an additional 5,184 shares during the period. Institutional investors own  7.25% of the company's stock. </p><h2>Journey Medical Stock Up 2.1%</h2><p>DERM stock opened at $7.92 on Friday. The firm has a market capitalization of $214.95 million, a price-to-earnings ratio of -22.63 and a beta of 0.80. The company's 50 day moving average price is $7.90 and its 200 day moving average price is $7.44. Journey Medical Corporation has a fifty-two week low of $3.54 and a fifty-two week high of $9.40. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.12 and a current ratio of 1.42. </p><p>Journey Medical (NASDAQ:DERM - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). The business had revenue of $17.63 million during the quarter, compared to analyst estimates of $18.85 million. Journey Medical had a negative net margin of 14.58% and a negative return on equity of 39.94%.  On average, equities research analysts anticipate that  Journey Medical Corporation will post -1.02 EPS for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of brokerages recently weighed in on DERM. HC Wainwright started coverage on Journey Medical in a research note on Monday, August 25th. They set a &#34;buy&#34; rating and a $13.00 price objective for the company. Zacks Research raised shares of Journey Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 13th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Journey Medical in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average price target of $12.17.</p><p><b>Read Our Latest Analysis on DERM</b></p><h2>Journey Medical Profile</h2> (Free Report)<p>Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Journey Medical</li><li>Large Cap Stock Definition and How to Invest</li><li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li><li>Best Energy Stocks - Energy Stocks to Buy Now</li><li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li></ul><p><strong>Want to see what other hedge funds are holding DERM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Journey Medical Corporation (NASDAQ:DERM - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Journey Medical Right Now?</h2><p>Before you consider Journey Medical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.</p><p>While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DERM

<p>Sheets Smith Investment Management acquired 132,904 shares of Journey Medical Corporation, valued at approximately $946,000, during the 3rd quarter. This acquisition represents about 0.51% ownership in the company. Other institutional investors have also adjusted their positions in Journey Medical. The company's stock opened at $7.92 with a market cap of $214.95 million. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and an average price target of $12.17.</p>

Sheets Smith Investment Management Invests $946,000 in Journey Medical Corporation $DERM